SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-043215
Filing Date
2021-08-11
Accepted
2021-08-11 06:20:57
Documents
61
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 INZY_10-Q_6312021 inzy-10q_20210630.htm   iXBRL 10-Q 2116840
2 EX-31.1 inzy-ex311_7.htm EX-31.1 20600
3 EX-31.2 inzy-ex312_6.htm EX-31.2 20621
4 EX-32.1 inzy-ex321_8.htm EX-32.1 9606
5 EX-32.2 inzy-ex322_9.htm EX-32.2 9663
  Complete submission text file 0001564590-21-043215.txt   7398407

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA inzy-20210630.xsd EX-101.SCH 40980
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE inzy-20210630_cal.xml EX-101.CAL 40710
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE inzy-20210630_def.xml EX-101.DEF 140637
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20210630_lab.xml EX-101.LAB 370156
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20210630_pre.xml EX-101.PRE 282208
11 EXTRACTED XBRL INSTANCE DOCUMENT inzy-10q_20210630_htm.xml XML 1401727
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39397 | Film No.: 211161887
SIC: 2834 Pharmaceutical Preparations